Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.52 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | CTSG | P08311 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2743774 | 0.84 | GABRA1 (0.62) | GABRA1GABRB2ELANECTSGSLC6A2 | |
| SCHEMBL1457233 | 0.80 | GABRA1 (0.52) | GABRA1GABRB2SLC6A2TAAR1MAOA | |
| Bromide SCHEMBL29193892 | 0.78 | GABRA1 (0.50) | GABRA1GABRB2SLC6A2TAAR1MAOA | |
| Hydrochloric Acid SCHEMBL29193867 | 0.78 | GABRA1 (0.50) | GABRA1GABRB2SLC6A2TAAR1MAOA | |
| Carbimide SCHEMBL28662233 | 0.77 | GABRA1 (0.54) | GABRA1GABRB2ELANECTSGSLC6A2 | |
| SCHEMBL2399172 | 0.75 | GABRA1 (0.52) | GABRA1GABRB2SLC6A2TAAR1MAOA | |
| SCHEMBL2042941 | 0.75 | GABRA1 (0.52) | GABRA1GABRB2ELANECTSGSLC6A2 | |
| SCHEMBL258656 | 0.75 | GABRA1 (0.63) | GABRA1GABRB2ELANECTSG | |
| SCHEMBL677035 | 0.75 | GABRA1 (0.52) | GABRA1GABRB2ELANECTSGSLC6A2 | |
| SCHEMBL2980083 | 0.75 | GABRA1 (0.52) | GABRA1GABRB2ELANECTSGSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111518145-B | Cyano-bridged metal organic compound with intramolecular magnetic transformation and preparation method and application thereof | 荆楚理工学院 | 2023-06-20 | — | — | CN | disclosed |
| EP-2610248-B1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING A PALLADIUM COMPOUND | TEIJIN PHARMA LTD (JP) | 2016-06-08 | — | — | EP | disclosed |
| US-8952174-B2 | Process for producing phenyl-substituted heterocyclic derivative through coupling using transition metal catalyst | TEIJIN PHARMA LIMITED (JP) | 2015-02-10 | — | — | US | disclosed |
| US-8916714-B2 | Method for producing phenyl-substituted heterocyclic derivative by means of coupling method using palladium compound | TEIJIN PHARMA LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| EP-2610248-A1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING A PALLADIUM COMPOUND | Teijin Pharma Limited (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-20130158272-A1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING PALLADIUM COMPOUND | TEIJIN PHARMA LIMITED (JP) | 2013-06-20 | — | — | US | disclosed |
| EP-2404908-A1 | PROCESS FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE THROUGH COUPLING USING TRANSITION METAL CATALYST | Teijin Pharma Limited (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-20110313169-A1 | PROCESS FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE THROUGH COUPLING USING TRANSITION METAL CATALYST | TEIJIN PHARMA LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-0732336-B1 | Process for the preparation of arylalkyl phosphines, arylalkyl phosphine oxides or arylalkyl phosphine sulfides | CYTEC CANADA INC (CA) | 2000-12-20 | — | — | EP | disclosed |
| EP-0732336-A1 | Process for the preparation of arylalkyl phosphines, arylalkyl phosphine oxides or arylalkyl phosphine sulfides | Cytec Canada Inc. (CA) | 1996-09-18 | — | — | EP | disclosed |
| US-5550295-A | Preparation of arylalkyl phosphines, phosphine oxides or phosphine sulfides | CYTEC TECHNOLOGY CORP. (US) | 1996-08-27 | — | — | US | disclosed |
| US-4668823-A | ARYLDICHLOROPHOSPHINE, TWO GRIGNARDS | UNION CARBIDE CORPORATION (US) | 1987-05-26 | — | — | US | disclosed |
| US-4257973-A | USING ORGANOPHOSPHORUS-PALLADIUM HALIDE COORDINATION CATALYST | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313169-A1 | PROCESS FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE THROUGH COUPLING USING TRANSITION METAL CATALYST | XDH, PAH, HPRT1 | GABRA1 3769/4885GABRB2 3881/4885ELANE 2496/4885 |
| US-20130158272-A1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING PALLADIUM COMPOUND | XDH, AOC1, PAH | GABRA1 2980/4885GABRB2 3492/4885ELANE 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.